Bitget App
Trade smarter
Buy cryptoMarketsTradeFuturesEarnAISquareMore
Bonk swings to Q2 FY26 net loss of $6.05 million; revenue rises to $1.16 million

Bonk swings to Q2 FY26 net loss of $6.05 million; revenue rises to $1.16 million

ReutersReuters2026/08/14 19:05
  • Bonk posted a net loss of USD 6.05 million for the quarter ended June 30, 2026, swinging from net income a year earlier.
  • Revenue rose to USD 1.16 million, including USD 792,937 in beverage sales and USD 370,469 in related-party revenue share.
  • Gross profit climbed to USD 391,050 from USD 23,878 a year earlier.
  • Operating expenses narrowed to USD 2.42 million from USD 4.36 million, while other income turned to expense at USD 4.02 million.
  • Management cited added sales from Yerbae Brands and a revenue share agreement with LetsBonk.fun as drivers of the revenue increase.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Bonk Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001493152-26-038241), on August 14, 2026, and is solely responsible for the information contained therein.

0
0

Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.

Understand the market, then trade.
Bitget offers one-stop trading for cryptocurrencies, stocks, and gold.
Trade now!

You may also like

Twice thwarted in a week! Novartis (NVS.US) fails in phase III trial for blockbuster heart disease drug, stock plummets; Amgen (AMGN.US) dragged down as well

Swiss pharmaceutical giant Novartis has suffered another clinical trial setback—within one week, the company’s second major drug candidate has failed in a late-stage study. This latest disappointment concerns its potential blockbuster heart disease drug pelacarsen.

智通财经2026/09/07 07:31
Twice thwarted in a week! Novartis (NVS.US) fails in phase III trial for blockbuster heart disease drug, stock plummets; Amgen (AMGN.US) dragged down as well